Tandem Diabetes Care Inc (NASDAQ:TNDM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) have been assigned an average rating of “Buy” from the fifteen analysts that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $74.58.

Several equities research analysts recently weighed in on TNDM shares. Oppenheimer raised their price target on shares of Tandem Diabetes Care from $80.00 to $84.00 in a research report on Friday, August 2nd. UBS Group raised shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price target for the company in a research report on Friday, October 4th. ValuEngine raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Guggenheim started coverage on shares of Tandem Diabetes Care in a research report on Thursday, October 17th. They set a “buy” rating and a $76.00 price target for the company. Finally, BidaskClub downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Friday, November 1st.

In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 6,969 shares of Tandem Diabetes Care stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $70.00, for a total value of $487,830.00. Following the completion of the sale, the executive vice president now owns 9,960 shares of the company’s stock, valued at approximately $697,200. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $72.00, for a total transaction of $144,000.00. Following the completion of the sale, the executive vice president now directly owns 5,311 shares of the company’s stock, valued at approximately $382,392. The disclosure for this sale can be found here. Insiders have sold 441,804 shares of company stock valued at $31,005,371 in the last three months. 6.90% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of TNDM. FMR LLC grew its position in Tandem Diabetes Care by 248.9% in the 1st quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock worth $44,818,000 after purchasing an additional 503,482 shares during the period. Chicago Capital LLC bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $14,641,000. Nisa Investment Advisors LLC grew its position in Tandem Diabetes Care by 53.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after purchasing an additional 160 shares during the period. Polianta Ltd bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $1,071,000. Finally, Foundry Partners LLC bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $1,860,000. 80.44% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ TNDM opened at $62.64 on Thursday. Tandem Diabetes Care has a fifty-two week low of $26.40 and a fifty-two week high of $74.81. The company has a 50 day simple moving average of $60.02 and a two-hundred day simple moving average of $63.83. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -24.56 and a beta of 0.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.05 and a current ratio of 2.46.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

See Also: Hedge Funds

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.